Revuforj revumenib
Drug Class
Menin-MLL inhibitorMenin-MLL 抑制剂
Mechanism
Inhibits the interaction between menin and MLL (KMT2A), turning off the transcription of oncogenic target genes in mutated leukemia cells.抑制 menin 与 MLL (KMT2A) 之间的相互作用，关闭突变白血病细胞中致癌靶基因的转录。
Approved Indication
Treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 30 days and older.用于治疗成人和30天及以上儿童患者的伴有 KMT2A 易位（MLL 重排）的复发或难治性急性白血病。
What This Means For Patients
Revuforj (revumenib) is a menin inhibitor developed to target acute leukemia containing KMT2A translocations (MLL rearrangements). It works by blocking aberrant chromatin complexes that drive cancer cell replication. It is available under the special-import policy in the Hainan Boao Lecheng pilot zone.瑞美尼布（Revuforj）是一种专门针对伴有 KMT2A 易位（MLL 重排）急性白血病的 menin 抑制剂。它通过阻断驱动癌细胞复制的异常染色质复合物发挥作用。该药物已通过先行区特许进口政策引入博鳌乐城。
Regulatory Approvals
- FDA — approved (2024) — label
Pivotal Clinical Evidence
- AUGMENT-101 — Issa et al., J Clin Oncol 2024 (NCT04065399) — DOI
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.